Digital health's point-solution era is giving way to broader platforms, and the cost-savings claims those platforms make to employers often don't hold up to methodological scrutiny.
News|Articles|February 3, 2026
From Decline to Growth: How One Brand Expanded Access in Late Lifecycle
Author(s)CoverMyMeds
This case study leverages IQVIA data and analytics to explore how one pharmaceutical brand navigated mature lifecycle stages in a competitive class, implementing seamless prior auth strategies with CoverMyMeds where a 22 percentage point claim approval rate lift was observed, on average, helping mitigate decreasing access.
Related to this article
CORXEL’s Dr. Bo Liang on why efficacy is no longer obesity medicine's biggest gap — and the four unmet needs that define what comes next.
MRD Testing Is Becoming the Most Important Tool in Oncology Drug Development: Q&A with Eric Matthews
MRD testing is transforming oncology trials — compressing timelines, enriching populations, and generating earlier answers.
Novo Nordisk data show real-world weight loss after switching to its oral semaglutide pill, FDA's peptide rulemaking stalls while its enforcement arm targets compounded peptide sellers, and Avi Pardo flags a compliance blind spot in field teams' text messages with doctors.
Dr. Jeremy Levin joins Ken Banta to share why he believes biotech's future demands a new level of leadership and stakeholder education — and why "mission without method" is a wasted effort.
Real-world data from Novo's Octane study show patients who switched from injectable GLP-1 therapy to oral semaglutide lost an average of 4.1% of their body weight within three months.
Numerof's Michael Abrams on why directing employees to the most effective, economical clinicians is digital health's most valuable offering.
Life sciences spends billions on compliance — but WhatsApp, iMessage, and SMS conversations between field teams and HCPs remain invisible to oversight.
Trending on PharmExec
1
Novo Reports Real-World Data Showing Weight Loss After Switch to Oral Semaglutide Pill
2
Roundup: Hengrui Pharma and Novo Enter Exclusive License Agreement for HRS-1596, AstraZeneca Enters Collaboartion with Summit Therapeutics
3
New U.S. Guidance Lays Out Exemptions for 100% Tariffs: Report
4
As Peptide Rulemaking Stalls, FDA Enforcement Moves Forward
5